What is HC Wainwright’s Estimate for Genmab A/S Q1 Earnings?

Genmab A/S (NASDAQ:GMAB) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Genmab A/S in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju expects that the company will earn $0.18 per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2025 earnings at $0.39 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.49 EPS and FY2025 earnings at $1.50 EPS.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter last year, the company earned $0.47 earnings per share.

Other research analysts also recently issued reports about the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Performance

Genmab A/S stock opened at $21.13 on Friday. The firm’s 50-day moving average is $21.08 and its 200-day moving average is $23.93. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88. The company has a market cap of $13.98 billion, a P/E ratio of 20.51, a PEG ratio of 0.57 and a beta of 0.97.

Institutional Trading of Genmab A/S

A number of large investors have recently modified their holdings of GMAB. Rhumbline Advisers increased its stake in Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after buying an additional 1,236 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Genmab A/S during the 2nd quarter worth $457,000. Finally, Sanctuary Advisors LLC acquired a new position in Genmab A/S in the 2nd quarter valued at $1,354,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.